Therapeutic Targeting Platform
Targeted, Flexible, Efficient
Our Zip-Code™ Technology platform is a first in class, cell-specific delivery system that can be used for a broad range of gene therapy applications. Because the Zip-Codes ™ are derived from an endogenous human mechanism it avoids all of the challenges of viral delivery approaches. The Zip-Codes ™ are universally applicable and specific for each cell type.
Our Science
Groundbreaking, Pioneering, Ushering in a New Era of Gene Therapies
Our science is redefining the boundaries of medicine, fueling new therapeutic approaches and providing a diversity of tools to oncologists and hope to families and patients with cancer.
About Us: Team and Advisors
Management Team
Anthony Johnson
Co-Founder & CEO
Anthony Johnson is an experienced executive with a strong track record of leadership across the healthcare sector. His experience has covered a multitude of areasMore details
Dr. Leon Bernal-Mizrachi
Co-Founder, CSO
Leon Bernal-Mizrachi, MD, is Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Bernal serves as theMore details
Dr. Stephen Chang Ph.D.
Senior Vice-President Research
Dr. Stephen Chang serves on the Scientific Advisory Board or Board of Directors for GT Biopharma, Orphesus Therapeutics, Cloak Therapeutics, Aegis Therapeutics and Legacy Therapeutics.More details
Contact Us
New York, NY 10014
1365 Clifton Road, Atlanta, GA 30322